ACUTE RETINAL NECROSIS AFTER ADMINISTRATION OF ADALIMUMAB, A SYSTEMIC ANTITUMOR NECROSIS FACTOR ANTIBODY.

MedStar author(s):
Citation: RETINAL Cases & Brief Reports. 12(4):307-309, 2018 Fall.PMID: 27997458Institution: MedStar Union Memorial HospitalDepartment: MedicineForm of publication: Journal ArticleMedline article type(s): Case Reports | Journal ArticleSubject headings: *Adalimumab/ae [Adverse Effects] | *Anti-Inflammatory Agents/ae [Adverse Effects] | *Retinal Necrosis Syndrome, Acute/ci [Chemically Induced] | Humans | Male | Middle Aged | Tumor Necrosis Factor-alpha/ai [Antagonists & Inhibitors]Year: 2018Local holdings: Available online through MWHC library: 2007 - presentISSN:
  • 1935-1089
Name of journal: Retinal cases & brief reportsAbstract: CONCLUSION: Physicians prescribing tumor necrosis factor alpha antagonist immunosuppressive therapy should be aware of the potential of developing acute retinal necrosis.METHODS: Case report.PURPOSE: To report a case of acute retinal necrosis in a patient on anti-tumor necrosis factor alpha immunosuppressive therapy.RESULTS: A 47-year-old man with psoriasis presented with blurred vision and floaters in the left eye 4 days after receiving his fourth dose of adalimumab, a tumor necrosis factor alpha antagonist. He was diagnosed with acute retinal necrosis and was treated with intravenous acyclovir as well as prophylactic laser barricade. Seven years later, he is 20/20 with no history of a retinal detachment.All authors: Campbell W, Garff K, Klima K, Schechet SA, Schocket LSFiscal year: FY2019Digital Object Identifier: Date added to catalog: 2018-09-28
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 27997458 Available 27997458

Available online through MWHC library: 2007 - present

CONCLUSION: Physicians prescribing tumor necrosis factor alpha antagonist immunosuppressive therapy should be aware of the potential of developing acute retinal necrosis.

METHODS: Case report.

PURPOSE: To report a case of acute retinal necrosis in a patient on anti-tumor necrosis factor alpha immunosuppressive therapy.

RESULTS: A 47-year-old man with psoriasis presented with blurred vision and floaters in the left eye 4 days after receiving his fourth dose of adalimumab, a tumor necrosis factor alpha antagonist. He was diagnosed with acute retinal necrosis and was treated with intravenous acyclovir as well as prophylactic laser barricade. Seven years later, he is 20/20 with no history of a retinal detachment.

English

Powered by Koha